VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Gain Therapeutics, Inc. (GANX) Total Return Calculator with Dividends Reinvested

Gain Therapeutics, Inc.

Popular:

The total return for Gain Therapeutics, Inc. (GANX) stock is +1.06% over the past 12 months. So far it's down 39.94% this year. The 5-year total return is -82.64%, meaning $10,000 invested in GANX stock 5 years ago would be worth $1,736 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in GANX 1 year ago, it would be worth $9,795 today — you'd have lost $205.

With Dividends Reinvested$9,795-2.05%

Price Only (No DRIP)$9,795-2.05%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in GANX

1Y$10,106+$106 (+1.1%)1.1% CAGR

3Y$3,590-$6,410 (-64.1%)-28.9% CAGR

5Y$1,736-$8,264 (-82.6%)-29.5% CAGR

10Y$1,705-$8,295 (-82.9%)-16.2% CAGR

15Y$1,705-$8,295 (-82.9%)-11.1% CAGR

20Y$1,705-$8,295 (-82.9%)-8.5% CAGR

30Y$1,705-$8,295 (-82.9%)-5.7% CAGR

Gain Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading GANX total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-39.94%	—	-39.94%	—	$6,006
1Y	+1.06%	1.06%	+1.06%	—	$10,106
3Y	-64.10%	-28.93%	-64.10%	—	$3,590
5Y	-82.64%	-29.54%	-82.64%	—	$1,736
10Y	-82.95%	-16.21%	-82.95%	—	$1,705
15Y	-82.95%	-11.12%	-82.95%	—	$1,705
20Y	-82.95%	-8.46%	-82.95%	—	$1,705
30Y	-82.95%	-5.73%	-82.95%	—	$1,705

Risk & Highlights

Best Year+38.79%2025

Worst Year-51.52%2021

Max Drawdown-61.24%2025-12-10 → 2026-02-05

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-17.92%	-17.92%	—	+0.41%	-18.3pp
2025	+38.79%	+38.79%	—	+16.64%	+22.2pp
2024	-40.50%	-40.50%	—	+24.00%	-64.5pp
2023	+0.93%	+0.93%	—	+24.81%	-23.9pp
2022	-42.46%	-42.46%	—	-19.95%	-22.5pp

GANX underperformed the S&P 500 by 30.26pp over the past year (+1.06% vs +31.32%).

Loading summary...

GANX Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
GANXGain Therapeutics, Inc.	$69M	+2.7%	-39.9%	+1.1%	—	-64.1%	-82.6%	-82.9%
PRAXPraxis Precision Medicines, Inc.	$7.6B	+9.0%	+18.0%	+860.9%	—	+2005.6%	-18.4%	-19.0%
ACMRACM Research, Inc.	$3.7B	+32.9%	+23.4%	+182.8%	—	+450.0%	+120.6%	+2861.5%
RAREUltragenyx Pharmaceutical Inc.	$2.5B	+13.4%	+9.9%	-26.0%	—	-44.9%	-77.6%	-58.9%
FOLDAmicus Therapeutics, Inc.	$4.5B	+0.3%	+1.5%	+134.1%	—	+19.0%	+50.9%	+125.0%
LGNDLigand Pharmaceuticals Incorporated	$4.6B	+14.2%	+22.3%	+125.1%	—	+200.3%	+83.9%	+95.1%
NTLAIntellia Therapeutics, Inc.	$1.6B	+4.1%	+50.4%	+91.0%	—	-67.9%	-79.2%	-37.3%
BEAMBeam Therapeutics Inc.	$3.3B	+33.4%	+19.1%	+102.2%	—	-3.0%	-53.9%	+72.4%
CRSPCRISPR Therapeutics AG	$5.3B	+12.1%	+2.4%	+66.1%	—	-1.6%	-48.9%	+290.9%
EDITEditas Medicine, Inc.	$311M	+16.7%	+54.9%	+138.7%	—	-67.0%	-90.8%	-89.5%
ILMNIllumina, Inc.	$21.7B	+11.6%	+6.1%	+91.3%	—	-25.0%	-61.1%	+4.3%

Compare:GANX vs PRAX GANX vs ACMR GANX vs RARE GANX vs PRAX vs ACMR

About GANX Dividend Returns

Gain Therapeutics, Inc. (GANX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of GANX over the past year?

Gain Therapeutics, Inc. (GANX) delivered a return of 1.06% over the past year. Since GANX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in GANX be worth today?

A $10,000 investment in Gain Therapeutics, Inc. one year ago would be worth $10,106 today, representing a gain of $106.

Q3Does GANX pay dividends?

Gain Therapeutics, Inc. (GANX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For GANX, the total return equals the price-only return.

Q4Did GANX beat the S&P 500?

No, Gain Therapeutics, Inc. (GANX) underperformed the S&P 500 by 30.26 percentage points over the past year. GANX delivered a total return of 1.06%, compared to the S&P 500's 31.32%. This means a passive S&P 500 index fund outperformed GANX by 30.26pp during this period.

Q5What is GANX's worst drawdown?

Gain Therapeutics, Inc. (GANX) experienced a maximum drawdown of -61.24% over the past year, declining from its peak on 2025-12-10 to its trough on 2026-02-05. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is GANX's long-term total return over 10, 20, or 30 years?

Here are Gain Therapeutics, Inc. (GANX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -82.9% (-16.2% CAGR) — $10,000 would have grown to $1,705. Over 20 years: -82.9% total return (-8.5% CAGR) — $10,000 → $1,705. Over 30 years: -82.9% total return (-5.7% CAGR) — $10,000 → $1,705. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was GANX's best and worst year?

Gain Therapeutics, Inc.'s best calendar year was 2025 with a total return of 38.8%. Its worst year was 2021 with a total return of -51.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 90.3 percentage points.